RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Clinical Trials
  Myocardial Infarction
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Clinical Trials Channel

subscribe to Clinical Trials newsletter
Latest Research : Cardiology : Clinical Trials

   EMAIL   |   PRINT
Aspirin of no use in primary prevention of cardiovascular events- POPADAD trial

Nov 1, 2008 - 2:33:57 AM , Reviewed by: Dr. Sanjukta Acharya

[RxPG] In the BMJ this week, the results of the POPADAD (the prevention of progression of arterial disease and diabetes)trial were presented. Antiplatelet agents have been known to reduce the risk of secondary cardiovascular events in patients with diabetes and cardiovascular disease and even in peripheral vascular disease. This study was to look at whether antiplatelets would help in the primary prevention of cardiovascular events in patients with diabetes and asymptomatic peripheral vascular disease.
Around 1270 adults with type1 and type 2 diabetes mellitus and with ankle brachial pressure index of 0.99 or less were taken into the study. The participants had no symptomatic cardiovascular disease, aged above 40 years and were from 16 hospitals in Scotland. They were assigned to recieve one of the following- aspirin and placebo, antioxidant and placebo, aspirin and antioxidant, or double placebo.The primary end points were death from coronary artery disease or stroke, non fatal myocardial infarction or stroke and amputation due to critical limb ischemia.
There was no difference in the primary end points in the aspirin vs. non aspirin groups(18.2% vs 18.3%) and no difference between the placebo vs. non placebo group (18.3 vs. 18.2).
There have been previous trials which have shown that aspirin is of no value in the primary prevention of cardiovascular events even in patients who are at high risk. This study helps to give more strength to this point. Perhaps now is the time for a rethink in clinical practice and change in guidelines which recommend the use of aspirin in high risk individuals with no existing cardiovascular disease.

Publication: BMJ 1st nov 2008

Advertise in this space for $10 per month. Contact us today.

Related Clinical Trials News
Aspirin of no use in primary prevention of cardiovascular events- POPADAD trial
Adipose-derived stem cells as a therapy for cardiovascular diseases ?
Pre hypertension best managed by early pharmacological intervention
Patients should not discontinue clopidogrel without consultation
Clopidogrel and aspirin combination fails to show long term beneficial affects in stable vascular patients
Bluhm Cardiovascular Institute Surgeons Implant Heart Pump in Comparative Study of Two Devices
Ground-breaking heart stem cell trial (REGENERATE) now underway

Subscribe to Clinical Trials Newsletter

Enter your email address:

 About Dr. Sanjukta Acharya
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS MRCP is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology. She can be reached for corrections and feedback at [email protected]
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)